Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monoclonal Antibody Duration of REsponse in MIgraine After Treatment Interruption: A Prospective National Study

NCT05232942 is registered in ClinicalTrials.gov with Hospital Clínico Universitario de Valladolid as lead sponsor.

NCT NCT05232942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05232942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monoclonal Antibody Duration of REsponse in MIgraine After Treatment Interruption: A Prospective National Study
Lead sponsor
Hospital Clínico Universitario de Valladolid
Phase
Observational
Overall status
Unknown status
Start date
February 15, 2022
Completion date
August 15, 2024
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

headache, migraine, migraine